Pfizer's stock has dropped by 1.31%, currently 0.02% shares of the company are owned by insiders while 73.5% are owned by Institutional investors.
On Monday, the shares of Pfizer dropped by 1.31% and traded at a share price of $34.41. The trading session on Monday started off with an initial share price of $33.1, during the course of the event was seen at a higher level of $33.325. While at the lower level, the share price reached up to $32.42.
The trading session on September 21, 2015 ended with a share price of $32.42 with the number of shares increasing at 23,705,054 shares. The pharmaceutical company’s market capital is $202.60 billion. At present, the outstanding shares in the company are 6,167,348,000.
In the short term, a target price estimate of $38.64 has been suggested for the Pfizer’s Stock. The target price is expected to fluctuate between $34 and $51. $51 being at the higher end of the target price and $34 being at the lower end of the target price has been recommended by eleven stock experts.
Pfizer’s stock price is said to vary between these numbers and a standard deviation has been calculated at $5.55. The pharmaceutical company witnessed a one year high share price at $36.46 and a one year low share price at $27.51. The 52-week high in the share prices was observed on July 31, 2015 while a 52-week low was seen on October 16, 2015. In the past one year, the share price has rallied by 8.85%.
The pharmaceutical company has received a rating of Hold in the short term, according to the stock analysts at Zacks, a research firm. The rank given to the shares of the pharmaceutical company by the stock experts at the research firm is 3 while 13 analysts have given an average rating of 1.92. Out of these 13 analysts, majority number of experts (eight) has suggested a Strong Buy on the shares of the company. Four have recommended a Hold rating on the company’s stock, whereas one has given it a rating of Strong Sell.
Insider Buying and Selling Activities information was revealed by the company to the SEC on a Form 4 filing stating that Pfizer’s Senior Vice President Cangialosi Lorettacarried out a transaction on July 30, 2015. According to the information that was provided to the Securities Exchange Commission, the Senior Vice President unloaded 24,704 shares at a share price of $35.65 each. This total transaction was worth $880,698. At present, Pfizer stock news reveals that company insiders own 0.02% of the company’s stock while institutional investors own 73.5%.
